Lisata Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Basking Ridge, NJ
LSTA chart
What traders are saying about $LSTA
Latest postsLisata Therapeutics, Inc. news
- Cholangiocarcinoma Market is Projected to Grow by 2036 Owing to Advances in Targeted Therapies and Immunotherapy | DelveInsight
StreetInsider ·
- Lisata Therapeutics, Inc. Estimates – NASDAQ:LSTA
TradingView ·
- Lisata Therapeutics, Inc. (LSTA) Stock Price, News, Quote & History
Yahoo Finance ·
- Lisata adds biopharma finance veteran Jeffrey Farrow to board
proactiveinvestors.com ·
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Yahoo Finance ·
- Lisata Therapeutics wins new US patent for pancreatic cancer drug
proactiveinvestors.com ·
- Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
Yahoo Finance ·
- Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial
proactiveinvestors.com ·
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Yahoo Finance ·
- MARKETS LIVE: Nasdaq hits record high as tech stocks lead Wall Street higher
proactiveinvestors.com ·
- Lisata subsidiary Marea Therapeutics gets late-breaking slot at AHA Scientific Sessions
proactiveinvestors.com ·
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Yahoo Finance ·
Lisata Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $170,000 | $1.0M | $0 | $0 |
| Net income | -$17.0M | -$20.0M | -$21.0M | -$54.2M |
| Diluted EPS | $-1.91 | $-2.40 | $-2.58 | $-10.47 |
| Total assets (year end) | $17.7M | $35.0M | $54.7M | $73.0M |
| Cash and equivalents (year end) | $16.0M | $16.2M | $22.6M | $32.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Lisata Therapeutics, Inc.
- Ticker
- LSTA (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Basking Ridge, NJ
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 320017
- Former names
- Caladrius Biosciences, Inc., CALADRIUS BIOSCIENCES, INC., NeoStem, Inc.
Frequently asked questions
What exchange is Lisata Therapeutics, Inc. listed on?
Lisata Therapeutics, Inc. trades on the Nasdaq under the ticker symbol LSTA.
What industry is Lisata Therapeutics, Inc. in?
Lisata Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Lisata Therapeutics, Inc. headquartered?
Lisata Therapeutics, Inc.'s business address on file with the SEC is in Basking Ridge, NJ.
When does Lisata Therapeutics, Inc.'s fiscal year end?
Lisata Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Lisata Therapeutics, Inc. report?
Lisata Therapeutics, Inc. reported $170,000 in revenue for calendar year 2025, according to its SEC filings.